Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) have partnered to create innovative enzymes aimed at treating orphan and rare diseases. This collaboration combines Selecta's ImmTOR technology, which has shown success in preclinical and clinical trials, with Ginkgo's advanced enzyme discovery capabilities. Under the agreement, Ginkgo could earn up to $85M in cash for milestone achievements and potential royalties on sales, signaling a promising step towards improving therapeutic options for patients with unmet medical needs.
Quest Diagnostics has entered an agreement with the Texas Department of State Health Services to provide COVID-19 testing services for K-12 schools, benefiting over 1,150 districts in Texas for the 2021-2022 school year. The program utilizes PCR and other nucleic acid amplification tests at Quest's clinical labs. Funding is provided through a CDC grant, ensuring no costs for schools or families. This initiative aims to promote safer in-person learning by enabling pooled testing.
Ginkgo Bioworks Inc. (NYSE: DNA) will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 3:00 p.m. Eastern Time. The company focuses on a platform for cell programming applicable to various markets, including biotechnology, pharmaceuticals, and industrial chemicals. Ginkgo has also supported COVID-19 initiatives, including vaccine optimization and testing. Investors can access the webcast and presentation replay via the company’s investor relations website.
Ginkgo Bioworks (NYSE: DNA) announced participation in two upcoming conferences. On October 7, 2021, management will attend the Cowen Annual MedTools Conference at 11:15 a.m. ET. Additionally, on October 13, 2021, they will engage in a fireside chat and 1x1 meetings at the Morgan Stanley Annual Spark Conference at 5:45 p.m. ET. For more information, visit their investor relations website.
On September 17, 2021, Ginkgo Bioworks and Soaring Eagle Acquisition Corp. announced the successful closure of their business combination. The newly formed entity, Ginkgo Bioworks Holdings, Inc., will trade on the NYSE under the symbols 'DNA' and 'DNA.WS'. This transaction, approved by Soaring Eagle stockholders on September 14, 2021, yields over $1.6 billion in proceeds and establishes Ginkgo's enterprise value at $15 billion. Ginkgo aims to leverage its cell programming platform to revolutionize various industries and address global challenges.
Ginkgo Bioworks has reported a significant surge in revenue for the first half of 2021, totaling $88 million, a 180% increase from the previous year. The company noted strong performance across its Foundry and Biosecurity sectors, with both sectors generating $44 million each. Ginkgo's business combination with Soaring Eagle Acquisition Corp. (SRNG) is expected to finalize shortly after a shareholder meeting on September 14, 2021, potentially providing up to $2.5 billion in gross cash proceeds. Ginkgo is also set to enhance its biosecurity services amid rising COVID-19 concerns.